Ahmed Mousa
Chief Executive Officer Vicore Pharma Holding
Ahmed Mousa, CEO of Vicore Pharma, brings a strong track record in corporate development, strategic partnerships, and pipeline advancement in the life sciences industry. At Vicore, he is leading efforts to pioneer novel treatments for idiopathic pulmonary fibrosis through modulation of the AT2 receptor pathway. Prior to Vicore, Ahmed was Chief Business Officer & General Counsel at Pieris Pharmaceuticals, where he drove key collaborations and pipeline growth. He also brings legal expertise from Covington & Burling and Kirkland & Ellis, advising biopharma companies on strategic and regulatory matters.
Seminars
As pulmonary fibrosis trials continue to expand globally, sponsors must navigate an increasingly complex operational landscape. Differences in regulatory expectations, site capabilities, patient access, and trial infrastructure across regions can significantly influence study timelines, enrolment success, and data quality.
Key Discussion Points Include:
- Navigating regional regulatory and ethics requirements, including how differing approval timelines, IRB/ethics committee expectations, and evolving regulations in emerging markets can impact global trial execution
- Strategies for identifying and activating high-performing sites, engaging investigators with varying levels of ILD expertise, and preventing under-enrolment or inactive sites across geographically diverse trial networks
- Managing the operational complexities of multinational trials, including drug distribution, cold chain logistics, imaging standardization, biomarker collection, and cross-border data integrity while maintaining compliance with GCP and regional privacy regulations
- Lessons from recent global IPF studies on designing scalable protocols, anticipating operational bottlenecks, and integrating hybrid or decentralized approaches to maintain efficiency without compromising data quality
The past year has been transformative for IPF, with new therapies, emerging mechanisms, and evolving patient management strategies reshaping the landscape. This panel will provide a strategic, forward-looking overview of how the field has progressed and what the next 12-18 months may hold. Panellists will discuss the expanding pathophysiology of IPF, emerging classifications of therapies, and implications for patient care, clinical development strategy, and communication with stakeholders.
Key Discussion Points:
- How newly approved therapies and emerging candidates are expected to influence IPF treatment and clinical and research priorities in the next 12–18 months.
- Exploring the practical impact of emerging terminology, anti-fibrotic, anti-inflammatory, de-differentiation, fibrolysis, and how these distinctions may shape patient and clinician preferences
- Approaches for ordering, timing, and combining therapies in a multi-drug era, balancing efficacy, safety, and operational feasibility.
- Identifying opportunities, challenges, and areas for collaboration to ensure trials and programs remain aligned with evolving clinical practice
